Immunic's (IMUX) Outperform Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Thursday morning, Benzinga reports. Wedbush currently has a $5.00 price target on the stock. Separately, StockNews.com began coverage on Immunic in a research report on Thursday, May 18th. They issued a sell rating on the stock. One […]